We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lombard Med.Tec | LSE:LMT | London | Ordinary Share | GB00B7FT8W85 | ORD 20P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 188.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLMT Lombard Medical Technologies PLC 06 April 2009 ? Press information Lombard Medical Technologies PLC ("Lombard Medical" or "Company") Positive Aorfix(TM) Data in Challenging Anatomies Reported at Charing Cross Symposium London, UK, 6 April 2009 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company, announces that Professor Michael Horrocks, Royal United Hospital, Bath, UK, has presented positive data from the use of Aorfix(TM) in patients with challenging anatomies at the 31st International Charing Cross Symposium (4-7th April). On 5th April Professor Horrocks presented data from Lombard Medical's Retrospective Aorfix(TM) Data Retrieval ("RADAR") voluntary registry. At the time of the analysis RADAR contained data on 619 implants out of more than 800 performed to date worldwide. Data for those patients for which sequential follow-up data was available continued to compare favourably with published data on the use of other stent grafts: +---------------------------------------+--------------------------------+ | | Aorfix(TM) | | | (April 2009) | +---------------------------------------+--------------------------------+ | All cause 30-day mortality | 1.45% (n=619) | | (of those fit for open surgery) | | +---------------------------------------+--------------------------------+ | Stent migration at 12 months | 0% (n=343) | +---------------------------------------+--------------------------------+ | Wire fracture at 12 months | < 0.5% (n=343) | +---------------------------------------+--------------------------------+ | Aneurysm rupture at 36 months | 0% (n=64) | +---------------------------------------+--------------------------------+ | Endoleaks at 12 months | 10.5% (7.6% type II) (n=343) | +---------------------------------------+--------------------------------+ Information on the aneurysm neck angle is held for 374 of the cases in RADAR and Professor Horrocks presented excellent clinical data on the performance of Aorfix(TM) in high-angle-neck patients (mean neck angle 80 ), for which there is currently no approved endovascular treatment. These data included an all cause mortality rate at 30-days of just 1.47% for the high-angle-neck patient group, which is significantly better than that for open surgery (approx. 4.8%) that is often the only alternative treatment available for such challenging cases. Despite the tortuous anatomy of the high-angle-neck patient group, no loss of patency (i.e. blood flow) or stent migration was observed at one year (n=73) and endoleak rates at 20.5% were similar to average rates quoted in studies of endovascular aneurysm repair (EVAR) of less difficult patients. Endoleak rates at one year for cases with neck-angles of < 60 (n=111) at just 9.0% (7.2% type II) demonstrated the value of using Aorfix(TM) in normal as well as difficult cases. Data was also presented on changes in the aneurysm diameter a year after implantation. This showed that in 97% of cases there was a decrease or no change (+/- 3mm) in aneurysm sac diameter indicating that the aneurysm was under control. Professor Horrocks commented: "Aorfix(TM) is likely to increase the number of patients considered suitable for EVAR who were previously excluded from this type of treatment and also reduce the risk of endoleaks." Brian Howlett, CEO of Lombard Medical, commented: "With more than 800 implantations of the AorfixTM worldwide there is a rapidly growing body of real world evidence supporting its clinical benefits in treating patients, this will increase the number of patients considered suitable for EVAR with difficult anatomies. The data presented by Professor Horrocks at the Charing Cross Symposium further underlines the major improvements seen in all cause mortality and other parameters for high-angle-neck patients compared with current NICE best practice and open surgery." Enquiries: +----------------------------------------------+----------------+ | Lombard Medical Technologies PLC | Tel: 01235 750 | | Simon Neathercoat, Non-executive Chairman | 800 | | Brian Howlett, Chief Executive Officer | | | Tim Hall, Finance Director | | +----------------------------------------------+----------------+ | | | +----------------------------------------------+----------------+ | Financial Dynamics | Tel: 020 7831 | | Jonathan Birt / Susan Quigley | 3113 | +----------------------------------------------+----------------+ | | | +----------------------------------------------+----------------+ | Nomura Code | Tel: 020 7776 | | Juliet Thompson / Richard Potts | 1200 | +----------------------------------------------+----------------+ Notes to editors About Lombard Medical Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment of vascular disease. The Company's lead product, Aorfix(TM), is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAAs), a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Approximately 1.7 million people have AAAs in the US where it is the 13th largest cause of death. The market for endovascular stent grafts for the treatment of AAA is currently worth over $600 million and is expected to grow to around a $1 billion by 2010. Aorfix(TM) is currently being commercialised in the EU, with a pivotal clinical trial ongoing in the USA. The Company's Polymer Coatings Division has developed a novel hydrophilic surface treatment to reduce friction on catheters called GlideMax(TM), which is available for licensing, and is using its polymer coating technology in a number of research collaborations developing novel products for the $5 billion drug-eluting stent market. The Company is headquartered in Oxfordshire, with operations in Yorkshire, Ayrshire and Boston, USA. Further background on the Company can be found at www.lombardmedical.com. This information is provided by RNS The company news service from the London Stock Exchange END NRAILFEASAIEIIA
1 Year Lombard Medical Technologies Chart |
1 Month Lombard Medical Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions